In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

The Next Generation of Gene Therapy Companies

This article was originally published in Start Up

Executive Summary

Despite problems with delivery and duration of expression, gene therapy still interests investors and entrepreneurs, who are pursuing new approaches.

You may also be interested in...



Mirus Corporation

Gene Therapy. Mirus is exploring technology for transfection reagents and has patents pending on certain protein, lipid and polyamine combinations for gene delivery. These formulations are designed to deliver DNA to cells with minimal toxicitiy. Mirus is already selling off-the-shelf transfection reagents which have been developed for gene transfer into cells in culture.

Calydon Inc.

Gene Therapy. Calydon is going after prostate cancer by delivering a prostate tissue-specific enhancer (PSE) gene to epithelial cells using an attenuated adenoviral vector.

Bavarian Nordic Research Institute GmbH

Gene Therapy. Bavarian Nordic avoids concerns about the pathogenicity of viral vectors with treatments based on modified vaccinia ankara (MVA) vectors and retroviral promoter conversion vectors. The company's MVA programs are focused on cancer, HIV infection and Dengue fever. It is developing {ProCon} for treatment of cancers of the breast and pancreas and potentially restenosis.

Related Content

Topics

UsernamePublicRestriction

Register

SC089710

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel